536 related articles for article (PubMed ID: 29580043)
21. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
22. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
Caglayan V; Onen E; Avci S; Sambel M; Kilic M; Oner S; Aydos MM; Yıldız HE
Arch Ital Urol Androl; 2019 Jan; 90(4):270-275. PubMed ID: 30655640
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
25. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
[TBL] [Abstract][Full Text] [Related]
26. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
27. Free and total PSA in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
[TBL] [Abstract][Full Text] [Related]
28. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer.
Sershon PD; Barry MJ; Oesterling JE
Eur Urol; 1994; 25(4):281-7. PubMed ID: 7519989
[TBL] [Abstract][Full Text] [Related]
29. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
O'Rourke DJ; DiJohnson DA; Caiazzo RJ; Nelson JC; Ure D; O'Leary MP; Richie JP; Liu BC
Clin Chim Acta; 2012 Mar; 413(5-6):561-7. PubMed ID: 22146597
[TBL] [Abstract][Full Text] [Related]
30. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Benson MC; Whang IS; Pantuck A; Ring K; Kaplan SA; Olsson CA; Cooner WH
J Urol; 1992 Mar; 147(3 Pt 2):815-6. PubMed ID: 1371554
[TBL] [Abstract][Full Text] [Related]
31. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
32. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker.
Gillatt D; Reynard JM
Br J Urol; 1995 Mar; 75(3):341-6. PubMed ID: 7537603
[TBL] [Abstract][Full Text] [Related]
33. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of prostate-specific antigen testing in patients with prostate disease.
Yu HJ; Chie WC; Hsieh CH; Tsai CC; Lai MK
J Formos Med Assoc; 1996 Oct; 95(10):782-8. PubMed ID: 8961676
[TBL] [Abstract][Full Text] [Related]
35. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
36. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Steuber T; Nurmikko P; Haese A; Pettersson K; Graefen M; Hammerer P; Huland H; Lilja H
J Urol; 2002 Nov; 168(5):1917-22. PubMed ID: 12394676
[TBL] [Abstract][Full Text] [Related]
37. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
38. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.
Martínez M; España F; Royo M; Vera CD; Estellés A; Jiménez-Cruz JF; Medina P; Aznar J
Eur Urol; 2000 Jul; 38(1):85-90. PubMed ID: 10859447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
